

S 2495

Protecting our Pharmaceutical Supply Chain from China Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jul 28, 2021

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Jul 28, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/2495>

Sponsor

Name: Sen. Cotton, Tom [R-AR]

Party: Republican • **State:** AR • **Chamber:** Senate

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Blackburn, Marsha [R-TN]	R · TN		Jul 28, 2021
Sen. Braun, Mike [R-IN]	R · IN		Jul 28, 2021
Sen. Cruz, Ted [R-TX]	R · TX		Jul 28, 2021
Sen. Scott, Rick [R-FL]	R · FL		Jul 28, 2021

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Jul 28, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 7121	Related bill	Mar 28, 2022: Referred to the Subcommittee on Health.
117 S 3401	Related bill	Dec 15, 2021: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Protecting our Pharmaceutical Supply Chain from China Act of 2021

This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing ingredients manufactured in China, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.

The Food and Drug Administration shall maintain (1) a list of foreign-sourced drugs and active ingredients that are critical for consumer health and safety, and (2) another list identifying such drugs that are produced exclusively in China or use ingredients produced in China.

The bill phases in a restriction on federal health care programs purchasing drugs with active ingredients manufactured in China. By January 1, 2024, such programs may not purchase a drug with any active ingredients from China. The Department of Health and Human Services may issue a waiver for an agency or program that is unable to meet this requirement, but no waiver may apply to drugs purchased in or after 2026.

Each drug must have labeling listing the country of origin of each active ingredient, and a drug without this labeling shall be deemed misbranded.

The bill allows 100% tax expensing for qualified pharmaceutical and medical device manufacturing property placed in service between 2020 and 2026.

Actions Timeline

- **Jul 28, 2021:** Introduced in Senate
- **Jul 28, 2021:** Read twice and referred to the Committee on Finance.